Resources

In this blog, Dr Emma Lawrence, Head of data tech policy and public affairs at BIA, writes about the UK government's recent £600 million initiative to launch a Health Data Research Service which aims to revolutionize access to NHS data and tackle longstanding governance and technical hurdles.

ELRIG, a not-for-profit, volunteer-led organisation dedicated to the drug discovery community, has appointed Dr Del Trezise as Chair of the Board.

Change is happening fast for our sector at the moment, and I expect to see big calls from the UK government as it responds to global events this week.

Andrew Merrison from FI Group shares his knowledge about the new rule changes HMRC has put in place concerning overseas costs about biotech.

Can “good bacteria” be used to maintain good health as we grow older? Scottish biotech company NCIMB has teamed up with the Rowett Institute to address this question.

Prof Rory Johnson, Associate Professor, University College Dublin and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca, will lead this year’s event, focussed on ‘drugging the undruggable’.

Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.

Maxion Therapeutics, a biotech company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, announced a $72 million raise in a Series A financing.

Co-designing new networks with research users is critical to delivering the full scientific and commercial value of NHS health data.

Intelligent upgrade of existing, purpose-built laboratory spaces will be available for occupation from Q3, 2025.

In this article, Giuseppe Amoroso, R&D Tax Advisor for biotech companies, explores the critical role of R&D tax compliance in the biotechnology sector.

The UK’s biotech sector continues to break new ground, from sustainable medicine manufacturing to AI-driven healthcare advancements. This week, I analyse key developments shaping the industry, including the launch of the Sustainable Medicine Manufacturing Innovation Programme, the BIA’s role in the government’s Spending Review, and the UK’s leadership in cultivated meat.

This latest research builds upon the growing body of evidence demonstrating the unique impact of Brainomix’s AI-powered software to expand access to life-changing stroke treatments across networks.

In this article, Dr. Fawzi Abou-Chahine, Grants Director at FI Group UK, delves into the evolving landscape of grant funding in the biotechnology sector.

The BIA is driving progress across life sciences, from shaping policy in engineering biology and advocating for balanced perspectives in the Covid Inquiry to exhibiting UK innovation at JP Morgan Healthcare Week. 

United Kingdom National Nuclear Laboratory and Medicines Discovery Catapult have received funding to drive the development of innovative approaches for new cancer treatments.